ClinicalTrials.gg
CompletedNCT03375463Updated Feb 5, 2024Results posted

A Study of Tirzepatide (LY3298176) in Healthy Participants

A Phase 1 interventional study of Tirzepatide and Tirzepatide in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-05.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study has four parts. Each participant will enroll in one part.

Part A: The purpose of Part A is to compare study drug tirzepatide solution formulation to a powder formulation mixed with water and given subcutaneously (SC) (just under the skin). Part A will measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it.

Part B: The purpose of Part B is to evaluate the safety and tolerability of tirzepatide intravenous (IV) formulation when administered into a vein.

Part C: The purpose of Part C is to evaluate the safety and tolerability of tirzepatide following multiple SC weekly doses of a solution.

Part D: The purpose of Part D is to evaluate the safety and tolerability of tirzepatide following single IV bolus dose of lyophilized formulation.

This study will last approximately 70 days for each part (Part A, Part B or Part D) and 92 days for Part C. This does not include screening. Screening is required within 28 days prior to the start of the study.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overtly healthy males or females, as determined by medical history and physical examination
  • Male participants: agree to use an effective method of for the duration of the study and for 3 months following the last dose of product
  • Female participants: not of due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause. Women with an intact uterus are deemed if they are greater than or equal to (≥)45 years old and have not taken hormones or oral contraceptives within the last year and had cessation of menses for at least 1 year. Or, have had at least 6 months of amenorrhea with follicle-stimulating hormone levels consistent with a postmenopausal state
  • Have a of 18.5 to 32.0 kilograms per meter squared (kg/m²) inclusive

Exclusion criteria

Exclusion Criteria:

  • Currently enrolled in a clinical trial involving an product or any other type of medical research judged not to be scientifically or medically compatible with this study
  • Received treatment with a drug that has not received regulatory approval for any indication within 30 days of screening
  • Have a history of heart block, or a pulse rate (PR) interval greater than (>)200 milliseconds (msec), or any abnormality in the 12-lead (ECG) at screening that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Have a significant history of or current cardiovascular (myocardial infarction, congestive heart failure, cerebrovascular accident, venous thromboembolism, etc.), respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological (including history of thrombocytopenia), or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study medication, or interfering with the interpretation of data
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    5 mg Tirzepatide SC (Solution)-Part A

    Participants received 5 milligrams (mg) of tirzepatide subcutaneous (SC) solution formulation.

    Drug: Tirzepatide

  • Experimental
    5 mg Tirzepatide SC (Lyophilized)-Part A

    Participants received 5 mg of tirzepatide SC lyophilized formulation.

    Drug: Tirzepatide

  • Experimental
    0.5 mg LY3298176 IV-Part B

    Participants received Intravenous (IV) infusion of a single 0.5 mg dose of tirzepatide formulation.

    Drug: Tirzepatide

  • Experimental
    5 mg/7.5 mg/ 10 mg Tirzepatide SC-Part C

    Participants received tirzepatide subcutaneous solution at 5 mg on Days 1 (week 1) and 8 (Week 2), 7.5 mg on Day 15 (Week 3) and 10 mg on Day 22 (Week 4).

    Drug: Tirzepatide

  • Placebo comparator
    Placebo SC-Part C

    Participants received SC injection of placebo.

    Drug: Placebo

  • Experimental
    0.5 mg LY3298176 Bolus IV-Part D

    Participants received IV bolus of 0.5 mg tirzepatide lyophilized formulation.

    Drug: Tirzepatide

Interventions

  • Administered SC

    Also known as: LY3298176

  • Administered IV

    Also known as: LY3298176

  • DrugPlacebo

    Administered SC

  • Administered IV

    Also known as: LY3298176

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK) Part A: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide

    Pharmacokinetics (PK) Part A: Area under the concentration versus time curve \[AUC (0-∞)\] of tirzepatide.

    Time frame: Part A: Predose, 8, 12, 24, 48, 72, 96, 120, 144, 168, 336, 480, 816-864 hours postdose

  2. PK Part A: Maximum Observed Drug Concentration (Cmax) of Tirzepatide

    PK Part A: Maximum observed plasma drug concentration (Cmax) of tirzepatide.

    Time frame: Part A: Predose, 8, 12, 24, 48, 72, 96, 120, 144, 168, 336, 480 and 816-864 hours postdose

  3. PK Part B: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide

    PK Part B: Area under the concentration versus time curve \[AUC (0-∞)\] of tirzepatide.

    Time frame: Part B: Predose, 0.08 hours (h), 0.16h, 0.5h, 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h, 336h, 816h-864h and >=70 days post dose

Secondary outcomes

  1. PK Part C: Area Under the Concentration Versus Time Curve [AUC (0-τ)] of Tirzepatide

    PK Part C: Area under the concentration versus time curve during one dosing interval (168 hours) \[AUC (0-τ)\] of tirzepatide.

    Time frame: Part C: Predose, 8 hours (h) (day (D)1), 24h (D2), 48h (D3),72h (D4), predose (D8), predose (D15), 8h (D15), 24h (D16), 48h (D17), 72h (D18), predose (D22), 8h (D22), 24h (D23), 48h (D24), 72h (D25), D57 and >= D96 postdose

  2. PK Part C: Maximum Observed Drug Concentration (Cmax) of Tirzepatide

    PK Part C: Maximum observed plasma drug concentration (Cmax) of tirzepatide.

    Time frame: Part C: Predose, 8 hours (h) (day (D)1), 24h (D2), 48h (D3),72h (D4), predose (D8), predose (D15), 8h (D15), 24h (D16), 48h (D17), 72h (D18), predose (D22), 8h (D22), 24h (D23), 48h (D24), 72h (D25), D57 and >= D96 postdose

  3. PK Part D: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide

    PK Part D: Area under the concentration versus time curve \[AUC (0-∞)\] of tirzepatide.

    Time frame: Part D: Predose, 0.08 hours (h), 0.16h, 0.5h, 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h, 336h, 816-864h and >= 70 days postdose

07

Results

Posted Feb 5, 2024

Participant flow

4-part study, Part A (2-period, 2-treatment, crossover study with at least 35 days of washout period), Part B (fixed, single-arm treatment study), Part C (placebo-controlled, 4-week dose escalation study) and Part D (a fixed, single-arm treatment study).

Period 1
Participant flow — Period 1
MilestoneSequence 1-Part ASequence 2-Part A0.5 mg Tirzepatide IV-Part BPlacebo SC-Part C5 mg/7.5 mg/ 10 mg Tirzepatide SC-Part C0.5 mg Tirzepatide Bolus IV-Part D
Started101084128
Received at least 1 dose of study drug101084128
Completed101074118
Not completed001010
Withdrew: Lost to follow-up001000
Withdrew: Adverse event000010
Period 2
Participant flow — Period 2
MilestoneSequence 1-Part ASequence 2-Part A0.5 mg Tirzepatide IV-Part BPlacebo SC-Part C5 mg/7.5 mg/ 10 mg Tirzepatide SC-Part C0.5 mg Tirzepatide Bolus IV-Part D
Started10100000
Received at least 1 dose of study drug10100000
Completed990000
Not completed110000
Withdrew: Lost to follow-up110000

Outcome measures

PrimaryPharmacokinetics (PK) Part A: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide

Pharmacokinetics (PK) Part A: Area under the concentration versus time curve \[AUC (0-∞)\] of tirzepatide.

Time frame:
Part A: Predose, 8, 12, 24, 48, 72, 96, 120, 144, 168, 336, 480, 816-864 hours postdose
Reported as:
Geometric mean · nanograms*hours per milliliter(ng*hr/mL)
Pharmacokinetics (PK) Part A: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide
nanograms*hours per milliliter(ng*hr/mL)5 mg Tirzepatide SC (Lyophilized)-Part A5 mg Tirzepatide SC (Solution)-Part A
Pharmacokinetics (PK) Part A: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide113000 ± 19109000 ± 17
PrimaryPK Part A: Maximum Observed Drug Concentration (Cmax) of Tirzepatide

PK Part A: Maximum observed plasma drug concentration (Cmax) of tirzepatide.

Time frame:
Part A: Predose, 8, 12, 24, 48, 72, 96, 120, 144, 168, 336, 480 and 816-864 hours postdose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
PK Part A: Maximum Observed Drug Concentration (Cmax) of Tirzepatide
nanograms per milliliter (ng/mL)5 mg Tirzepatide SC (Lyophilized)-Part A5 mg Tirzepatide SC (Solution)-Part A
PK Part A: Maximum Observed Drug Concentration (Cmax) of Tirzepatide524 ± 27575 ± 22
PrimaryPK Part B: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide

PK Part B: Area under the concentration versus time curve \[AUC (0-∞)\] of tirzepatide.

Time frame:
Part B: Predose, 0.08 hours (h), 0.16h, 0.5h, 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h, 336h, 816h-864h and >=70 days post dose
Reported as:
Geometric mean · ng*hr/mL
PK Part B: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide
ng*hr/mL0.5 mg Tirzepatide IV-Part B
PK Part B: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide6680 ± 26
SecondaryPK Part C: Area Under the Concentration Versus Time Curve [AUC (0-τ)] of Tirzepatide

PK Part C: Area under the concentration versus time curve during one dosing interval (168 hours) \[AUC (0-τ)\] of tirzepatide.

Time frame:
Part C: Predose, 8 hours (h) (day (D)1), 24h (D2), 48h (D3),72h (D4), predose (D8), predose (D15), 8h (D15), 24h (D16), 48h (D17), 72h (D18), predose (D22), 8h (D22), 24h (D23), 48h (D24), 72h (D25), D57 and >= D96 postdose
Reported as:
Geometric mean · ng*hr/mL
PK Part C: Area Under the Concentration Versus Time Curve [AUC (0-τ)] of Tirzepatide
ng*hr/mL5 mg Tirzepatide SC-Part C7.5 mg Tirzepatide SC-Part C10 mg Tirzepatide SC-Part C
PK Part C: Area Under the Concentration Versus Time Curve [AUC (0-τ)] of Tirzepatide68900 ± 19149000 ± 26—
SecondaryPK Part C: Maximum Observed Drug Concentration (Cmax) of Tirzepatide

PK Part C: Maximum observed plasma drug concentration (Cmax) of tirzepatide.

Time frame:
Part C: Predose, 8 hours (h) (day (D)1), 24h (D2), 48h (D3),72h (D4), predose (D8), predose (D15), 8h (D15), 24h (D16), 48h (D17), 72h (D18), predose (D22), 8h (D22), 24h (D23), 48h (D24), 72h (D25), D57 and >= D96 postdose
Reported as:
Geometric mean · ng/mL
PK Part C: Maximum Observed Drug Concentration (Cmax) of Tirzepatide
ng/mL5 mg Tirzepatide SC-Part C7.5 mg LY3298176 SC-Part C10 mg Tirzepatide SC-Part C
PK Part C: Maximum Observed Drug Concentration (Cmax) of Tirzepatide663 ± 231270 ± 241900 ± 24
SecondaryPK Part D: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide

PK Part D: Area under the concentration versus time curve \[AUC (0-∞)\] of tirzepatide.

Time frame:
Part D: Predose, 0.08 hours (h), 0.16h, 0.5h, 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h, 336h, 816-864h and >= 70 days postdose
Reported as:
Geometric mean · ng*hr/mL
PK Part D: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide
ng*hr/mL0.5 mg Tirzepatide Bolus IV-Part D
PK Part D: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide14000 ± 16

Adverse events

Collected over Up To 92 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5 mg Tirzepatide SC (Lyophilized)-Part A0/20 (0%)0/20 (0%)9/20 (45%)
5 mg Tirzepatide SC (Solution)-Part A0/20 (0%)0/20 (0%)5/20 (25%)
0.5 mg Tirzepatide IV-Part B0/8 (0%)0/8 (0%)1/8 (12.5%)
Placebo SC-Part C0/4 (0%)0/4 (0%)1/4 (25%)
5 mg Tirzepatide SC, First-Part C0/12 (0%)0/12 (0%)4/12 (33.3%)
5 mg Tirzepatide SC, Second Dose-Part C0/12 (0%)0/12 (0%)2/12 (16.7%)
7.5 mg LY3298176 SC-Part C0/12 (0%)0/12 (0%)6/12 (50%)
10 mg Tirzepatide SC-Part C0/11 (0%)0/11 (0%)4/11 (36.4%)
0.5 mg Tirzepatide Bolus IV-Part D0/8 (0%)0/8 (0%)3/8 (37.5%)
Most frequent other events
Showing 10 of 19
Most frequent other events
Event5 mg Tirzepatide SC (Lyophilized)-Part A5 mg Tirzepatide SC (Solution)-Part A0.5 mg Tirzepatide IV-Part BPlacebo SC-Part C5 mg Tirzepatide SC, First-Part C5 mg Tirzepatide SC, Second Dose-Part C7.5 mg LY3298176 SC-Part C10 mg Tirzepatide SC-Part C0.5 mg Tirzepatide Bolus IV-Part D
Injection site reactionGeneral disorders5/202/200/80/40/120/122/123/110/8
HeadacheNervous system disorders1/200/200/81/40/120/120/123/110/8
NauseaGastrointestinal disorders4/202/200/80/42/120/123/121/110/8
Abdominal painGastrointestinal disorders2/203/200/80/40/121/122/121/110/8
DizzinessNervous system disorders0/200/200/80/40/120/122/120/110/8
DiarrhoeaGastrointestinal disorders3/201/200/80/40/120/121/120/110/8
DysphagiaGastrointestinal disorders0/200/200/80/40/120/120/120/111/8
OdynophagiaGastrointestinal disorders0/200/200/80/40/120/120/120/111/8
ToothacheGastrointestinal disorders0/200/200/80/40/120/120/120/111/8
GastroenteritisInfections and infestations0/200/201/80/40/120/121/120/110/8

Baseline characteristics

All randomized participants

Age, Categorical
Age, Categorical(Participants)Sequence 1-Part ASequence 2-Part A0.5 mg Tirzepatide IV-Part BPlacebo SC-Part C5 mg/7.5 mg/ 10 mg Tirzepatide SC-Part C0.5 mg Tirzepatide Bolus IV-Part DTotal
<=18 years0000000
Between 18 and 65 years10108411851
>=65 years0000101
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1-Part ASequence 2-Part A0.5 mg Tirzepatide IV-Part BPlacebo SC-Part C5 mg/7.5 mg/ 10 mg Tirzepatide SC-Part C0.5 mg Tirzepatide Bolus IV-Part DTotal
Female22007415
Male88845437
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sequence 1-Part ASequence 2-Part A0.5 mg Tirzepatide IV-Part BPlacebo SC-Part C5 mg/7.5 mg/ 10 mg Tirzepatide SC-Part C0.5 mg Tirzepatide Bolus IV-Part DTotal
Hispanic or Latino3111129
Not Hispanic or Latino797311643
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence 1-Part ASequence 2-Part A0.5 mg Tirzepatide IV-Part BPlacebo SC-Part C5 mg/7.5 mg/ 10 mg Tirzepatide SC-Part C0.5 mg Tirzepatide Bolus IV-Part DTotal
American Indian or Alaska Native0000000
Asian0110002
Native Hawaiian or Other Pacific Islander0000000
Black or African American57328429
White52424320
More than one race0000011
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(participants)Sequence 1-Part ASequence 2-Part A0.5 mg Tirzepatide IV-Part BPlacebo SC-Part C5 mg/7.5 mg/ 10 mg Tirzepatide SC-Part C0.5 mg Tirzepatide Bolus IV-Part DTotal
United States10108412852
08

Study locations

1 site
  • Covance
    Dallas, Texas 75247, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Dec 2018, 12 months.

Results were first posted in Feb 2024, 5 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2017
First posted
Dec 18, 2017
StartActual
Dec 19, 2017
Primary completionActual
Dec 27, 2018
CompletionActual
Dec 27, 2018
Results first posted
Feb 5, 2024
Last update
Feb 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03375463
Responsible party
Sponsor
First posted
Dec 18, 2017
Start date
Dec 19, 2017
Primary completion
Dec 27, 2018
Completion
Dec 27, 2018
Results posted
Feb 5, 2024
Last update
Feb 5, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion